Business
AstraZeneca chief quits CSL board over $50 billion acquisition – Sydney Morning Herald
AstraZeneca’s Pascal Soriot will depart the CSL board next month to prevent potential conflicts of interest after his company bought a US immunology startup.
AstraZeneca announced its planned acquisition of Alexion for $US39 billion ($50.4 billion) in the second week of December, with Mr Soriot telling his investors the deal would allows us to enhance our presence in immunology.
Based in Boston, Alexion develops treatments for rare diseases including in the blood and heart conditions, where CSL is a major player.
CSL, which is producing doses of AstraZenecas COVID-19 vaccine in Australia, told investors last year that Mr Soriots appointment did not look…
-
Noosa News15 hours agoIncrease in extreme weather events poses ‘substantial risk’ to blood supplies, researchers warn
-
Noosa News23 hours agoTributes flow for Geham wife and mother after husband charged with murder
-
General22 hours agoABC Leaders Debate revealed gaps for both Peter Dutton and Anthony Albanese
-
Noosa News15 hours ago‘Low morale, decreasing trust in leadership’: Top cop’s stark warning